These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 7686593

  • 1. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH.
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [Abstract] [Full Text] [Related]

  • 2. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation.
    Wachtfogel YT, Kettner C, Hack CE, Nuijens JH, Reilly TM, Knabb RM, Kucich U, Niewiarowski S, Edmunds LH, Colman RW.
    Thromb Haemost; 1998 Oct; 80(4):686-91. PubMed ID: 9798991
    [Abstract] [Full Text] [Related]

  • 3. Alpha 1-antitrypsin Pittsburgh (Met358-->Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation.
    Wachtfogel YT, Bischoff R, Bauer R, Hack CE, Nuijens JH, Kucich U, Niewiarowski S, Edmunds LH, Colman RW.
    Thromb Haemost; 1994 Dec; 72(6):843-7. PubMed ID: 7740452
    [Abstract] [Full Text] [Related]

  • 4. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.
    Gikakis N, Khan MM, Hiramatsu Y, Gorman JH, Hack CE, Sun L, Rao AK, Niewiarowski S, Colman RW, Edmunds LH.
    Circulation; 1996 Nov 01; 94(9 Suppl):II341-6. PubMed ID: 8901772
    [Abstract] [Full Text] [Related]

  • 5. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation.
    Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH, Koneti Rao A, Sun L, Cooper SL, Colman RW.
    Thromb Haemost; 1996 Jan 01; 75(1):76-82. PubMed ID: 8713783
    [Abstract] [Full Text] [Related]

  • 6. Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.
    Hiramatsu Y, Homma S, Sato Y, Sato S, Matsuzaki K, Shigeta O, Sakakibara Y.
    Ann Thorac Surg; 2005 Apr 01; 79(4):1326-32. PubMed ID: 15797071
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y, Hiramatsu Y, Watanabe Y, Yoshimura Y, Sakakibara Y.
    Ann Thorac Surg; 2004 Feb 01; 77(2):644-50. PubMed ID: 14759453
    [Abstract] [Full Text] [Related]

  • 11. Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation.
    Rinder CS, Smith MJ, Rinder HM, Cortright DN, Brodbeck RM, Krause JE, Smith BR.
    Ann Thorac Surg; 2007 Jan 01; 83(1):146-52. PubMed ID: 17184649
    [Abstract] [Full Text] [Related]

  • 12. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation.
    Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch J, Li L, Rollins SA, Smith BR.
    J Thorac Cardiovasc Surg; 1999 Sep 01; 118(3):460-6. PubMed ID: 10469960
    [Abstract] [Full Text] [Related]

  • 13. Elastase release following myocardial ischemia during extracorporeal circulation (ECC) -- marker of ongoing systemic inflammation?
    Boeken U, Feindt P, Schulte HD, Gams E.
    Thorac Cardiovasc Surg; 2002 Jun 01; 50(3):136-40. PubMed ID: 12077684
    [Abstract] [Full Text] [Related]

  • 14. Sivelestat reduces inflammatory mediators and preserves neutrophil deformability during simulated extracorporeal circulation.
    Matsuzaki K, Hiramatsu Y, Homma S, Sato S, Shigeta O, Sakakibara Y.
    Ann Thorac Surg; 2005 Aug 01; 80(2):611-7. PubMed ID: 16039215
    [Abstract] [Full Text] [Related]

  • 15. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
    Kondo N, Wakayama F, Suzuki Y, Fukui K, Takaya S, Fukuda I.
    Thromb Res; 2004 Aug 01; 113(5):303-10. PubMed ID: 15183042
    [Abstract] [Full Text] [Related]

  • 16. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
    van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR.
    J Thorac Cardiovasc Surg; 1990 May 01; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
    [Abstract] [Full Text] [Related]

  • 17. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
    Baufreton C, Velthuis HT, Jansen PG, Besnerais PL, Wildevuur CH, Loisance DY.
    ASAIO J; 1996 May 01; 42(5):M417-23. PubMed ID: 8944919
    [Abstract] [Full Text] [Related]

  • 18. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, Hack CE.
    J Clin Invest; 1993 Mar 01; 91(3):1035-43. PubMed ID: 8450033
    [Abstract] [Full Text] [Related]

  • 19. Human neutrophil degranulation during extracorporeal circulation.
    Wachtfogel YT, Kucich U, Greenplate J, Gluszko P, Abrams W, Weinbaum G, Wenger RK, Rucinski B, Niewiarowski S, Edmunds LH.
    Blood; 1987 Jan 01; 69(1):324-30. PubMed ID: 2947645
    [Abstract] [Full Text] [Related]

  • 20. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT, Fung M, Bergseth G, Riesenfeld J, Lambris JD, Videm V, Mollnes TE.
    Ann Thorac Surg; 2004 Mar 01; 77(3):932-41. PubMed ID: 14992902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.